

Price Sensitive Information

The Meeting of the Board of Directors of Beacon Pharmaceuticals PLC held on 22 October 2023 at 4.00 PM at its Corporate Office at Beacon Business Centre, 9/B/2, Toyenbee Circular Road, Motijheel C/A, Dhaka-1223 has approved the Audited Financial Statements of the Company for the year ended 30 June 2023 and has decided, declared and recommended the following price sensitive information accordingly:

Date & time of the 22nd AGM : 24 December 2023 at 11.00 am
through digital platform.

Venue : Digital Platform
Record Date : 16 November 2023
Recommended Dividend : 16% Cash

The Board also declared the following financial information:

Earning Per Share (EPS) : Tk. 2.21
Net Asset Value Per Share (NAVPS) : Tk. 25.72
Net Operating Cash Flow Per Share (NOCFPS) : Tk. 2.69

The Comparative statement of financial information in respect of previous year is as follows:

Sl.No.	Particulars	Yr. 2022-23	Yr. 2021-22
01	Earning Per Share (EPS)	Tk. 2.21	Tk. 4.05
02	Net Asset Value Per Share (NAVPS)	Tk. 25.72	Tk. 25.73
03	Net Operating Cash Flow Per Share (NOCFPS)	Tk. 2.69	Tk. 4.68

Date : 22.10.2023

By order of the Board of Directors

BEACON[®]
Pharmaceuticals PLC

Beacon Business Centre
9/B/2, Toyenbee Circular Road, Motijheel, Dhaka-1223



Khalilur Rahman FCS
Company Secretary

- Hon'ble Shareholders are requested to update the particulars of their BO ID with mailing address, contact number, email ID and 12 Digit Taxpayer's Identification Number (e-TIN) through Depository Participants (DP) before the record date.
- Failure to provide e-TIN to Depository Participants, Tax to be deducted @ 15% instead of 10% (Individual) as per Section 54 of Income Tax Ordinance 1984.

3C X 6 Inch